Medicus Pharma Ltd. (MDCX)
Nasdaq: MDCX · Pharmaceutical Preparations · W. Conshohocken, PA · filing with the SEC since 2023
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 25, 2026 | Mar 28, 2025 | · |
| For lenders | |||
| Net interest income | -197,382 | 25,386 | · |
| Research and development | 7,721,436 | 3,527,786 | 193,578 |
| General and administrative | 17,920,391 | 7,653,116 | 4,536,367 |
| Total operating expenses | 34,359,302 | 11,180,902 | 4,729,945 |
| Operating income | -34,359,302 | -11,180,902 | -4,729,945 |
| Interest and investment income | · | 25,386 | -584,820 |
| Other income (expense), net | -1,085,059 | 25,386 | -584,820 |
| Income tax expense | 0 | 0 | 0 |
| Net income including non-controlling interests | -35,444,361 | -11,155,516 | -5,314,765 |
| Net income to non-controlling interests | -146 | 0 | · |
| Net income | -47,281,513 | -11,155,516 | -5,314,765 |
| Net income to common shareholders | -47,281,659 | -11,155,516 | -5,314,765 |
| Earnings per share, basic | -2.74 | -1.16 | -1.53 |
| Earnings per share, diluted | -2.74 | -1.16 | -1.53 |
| Weighted average shares, basic | 17,283,824 | 9,619,184 | 3,479,494 |
| Weighted average shares, diluted | 17,283,824 | 9,619,184 | 3,479,494 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding